Clinical trial · no report yet · Phase 3
NCT03066778
A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604)
- NCT03066778 ↗
- Completed
- Merck Sharp & Dohme LLC
- 19 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 12 | |
| Podcasts | 4 | |
| YouTube | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3 Randomized, Double-Blind, Placebo-controlled Trial of Pembrolizumab (MK-3475/SCH900475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for the First-line Treatment of Subjects With Extensive Stage Small Cell Lung Cancer (KEYNOTE-604)
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Small Cell Lung Cancer (SCLC)
- Interventions
- Pembrolizumab; Normal saline solution; Carboplatin; Cisplatin; Etoposide
- Arms
- Pembrolizumab+EP · Experimental
- Placebo+EP · Active comparator
- Enrollment
- 453
- Primary outcomes
- Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)
- Overall Survival (OS)
- Sponsor
- Merck Sharp & Dohme LLC
- Start
- May 2, 2017
- Primary completion
- Dec 2, 2019
- Results posted
- Yes
- Registry record
- NCT03066778 · updated Oct 3, 2022
Publications
linked from the registry- Rudin CM, Awad MM, Navarro A, Gottfried M, Peters S, Csoszi T, Cheema PK, Rodriguez-Abreu D, Wollner M, Yang JC, Mazieres J, Orlandi FJ, Luft A, Gumus M, Kato T, Kalemkerian GP, Luo Y, Ebiana V, Pietanza MC, Kim HR; KEYNOTE-604 Investigators. Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study. J Clin Oncol. 2020 Jul 20;38(21):2369-2379. doi: 10.1200/JCO.20.00793. Epub 2020 May 29. PubMed 32468956